1 | 10146 | LAO-CT018 | ETCTN | Breast Cancer | Active | Randomized Phase 2 Clinical Trial of Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab + Neoantigen Vaccine Vs. Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab in Patients with Metastatic Triple Negative Breast Cancer | II | 27/70 | N/A | INTERVENTION |
2 | 10222 | LAO-CT018 | ETCTN | Gastrointestinal Cancer;Solid Tumor | Temporarily Closed to Accrual | A Phase II Study of Olaparib and AZD6738 in Isocitrate Dehydrogenase (IDH) Mutant Solid Tumors | II | 24/50 | N/A | INTERVENTION |
3 | 10292 | LAO-NCI | ETCTN | Solid Tumor | Active | DURVA+ : Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody Durvalumab in Combination with Chemotherapy in Patients with Advanced Solid Tumors | II | 74/115 | N/A | INTERVENTION |
4 | 10330 | LAO-CT018 | ETCTN | Bone Cancer | Temporarily Closed to Accrual | A Phase 2 Study of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma | II | 19/32 | N/A | INTERVENTION |
5 | 10504 | LAO-NCI | ETCTN | Soft Tissue Cancer/Sarcoma | Active | A Randomized Phase 2 Study of Atezolizumab with or Without Selinexor in Alveolar Soft Part Sarcoma (AXIOM) | II | 8/77 | N/A | INTERVENTION |
6 | 10507 | LAO-MA036 | ETCTN | Miscellaneous and Metastatic Cancer | Active | A Phase 1/2 Study of the Bromodomain Inhibitor ZEN003694 in Combination with Etoposide/Platinum in Patients with NUT Carcinoma | I/II | 12/18 | N/A | INTERVENTION |
7 | 10579 | LAO-PA015 | ETCTN | Gastrointestinal Cancer;Solid Tumor | Active | Phase I Trial of ZEN003694 (ZEN-3694) in Combination with Capecitabine in Patients with Solid Tumors | I | 4/30 | N/A | INTERVENTION |
8 | 10603 | LAO-MA036 | ETCTN | Male Reproductive System Cancer | Active | A Phase 2 Study of M1774 in Refractory SPOP-Mutant Prostate Cancer | II | 2/17 | N/A | INTERVENTION |
9 | 10612 | LAO-CT018 | ETCTN | Myeloma | Active | A Randomized Phase 2 Study of Daratumumab-Selinexor-Velcade-Dexamethasone (Dara-SVD) for High-Risk Newly Diagnosed Multiple Myeloma | II | 0/70 | N/A | INTERVENTION |
10 | 10324 | LAO-MD017 | ETCTN | Female Reproductive System Cancer | Active | A Phase I/Ib Dose Escalation Study of Pegylated Liposomal Doxorubicin (PLD) with Peposertib (M3814) in Platinum - Resistant or Ineligible Ovarian and Related Cancers with Planned Expansions in High Grade Serous (HGSOC) and Low Grade Serous Ovarian Cancer (LGSOC) | I | 51/49 | N/A | INTERVENTION |
11 | 10327 | LAO-CA043 | ETCTN | Lung, Mediastinal, and Pleural Cancer | Active | A Phase I Trial of MLN0128 (Sapanisertib) and Telaglenastat (CB-839) HCL in Advanced NSCLC Patients | I | 19/85 | N/A | INTERVENTION |
12 | 10335 | LAO-CT018 | ETCTN | Leukemia;Lymphoma | Active | A Phase 1 Study of Lenalidomide in Combination with EPOCH Chemotherapy for HTLV-Associated Adult T-Cell Leukemia-Lymphoma (ATLL) | I | 10/30 | N/A | INTERVENTION |
13 | 10487 | LAO-MD017 | ETCTN | Male Reproductive System Cancer | Active | A Phase II Study of Lutetium Lu 177 Dotatate in Metastatic Prostate Cancer with Neuroendocrine Differentiation | II | 4/30 | N/A | INTERVENTION |
14 | 10496 | LAO-CA043 | ETCTN | Head and Neck Cancer | Active | A Phase 2 Study of Ipatasertib in Combination with Pembrolizumab for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck | II | 25/52 | N/A | INTERVENTION |
15 | 10508 | LAO-MA036 | ETCTN | Lymphoma | Active | A Phase 1 Study of Nivolumab in Combination with ASTX727 in B-cell Lymphoma (NHL or HL) with an Expansion Cohort in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | I | 8/27 | N/A | INTERVENTION |
16 | 10546 | LAO-MA036 | ETCTN | Breast Cancer | Active | Phase I Study Targeting DNA Methyltransferases in Metastatic Triple-Negative Breast Cancer | I | 6/24 | N/A | INTERVENTION |
17 | 10558 | LAO-OH007 | ETCTN | Endocrine Cancer | Active | A Phase II Randomized Control Trial of Triapine Plus Lutetium Lu 177 Dotatate Versus Lutetium Lu 177 Dotatate Alone for Well-Differentiated Somatostatin Receptor-Positive Neuroendocrine Tumors | II | 25/94 | N/A | INTERVENTION |
18 | 10559 | LAO-11030 | ETCTN | CNS Cancer (Primary tumor) | Active | A Phase 2 Study of Erdafitinib in Patients with Recurrent or Progressive IDH-Wild Type Glioma with an FGFR-TACC Gene Fusion | II | 1/35 | N/A | INTERVENTION |
19 | 10561 | LAO-NCI | ETCTN | Solid Tumor | Active | Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 3 Tiragolumab + Atezolizumab | II | 4/15 | N/A | INTERVENTION |
20 | 10273 | LAO-CA043 | ETCTN | Leukemia | Temporarily Closed to Accrual | A Phase I Study of M3814 in Combination with MEC in Patients with Relapsed or Refractory Acute Myeloid Leukemia | I | 25/48 | N/A | INTERVENTION |
21 | 10346 | LAO-NCI | ETCTN | Solid Tumor | Active | Pilot Study of DS-8201a Pharmacodynamics in Patients with HER2-Expressing Advanced Solid Tumors | I | 62/55 | N/A | INTERVENTION |
22 | 10434 | LAO-OH007 | ETCTN | Leukemia | Active | Randomized Phase 2 Study of Daunorubicin and Cytarabine Liposome + Pomalidomide Versus Daunorubicin and Cytarabine Liposome in Newly Diagnosed AML with MDS-Related Changes | II | 28/78 | N/A | INTERVENTION |
23 | 10464 | EDDO-MI014 | ETCTN | Gastrointestinal Cancer | Temporarily Closed to Accrual | A Phase 1 Study of Olaparib in Combination with Durvalumab (MEDI4736) and Concurrent Radiation Therapy Following First-Line Chemotherapy in Locally Advanced Unresectable Pancreatic Cancer | I | 7/18 | N/A | INTERVENTION |
24 | 10483 | LAO-11030 | ETCTN | Urothelial/ Bladder Cancer | Active | Phase Ib Trial of Erdafitinib Combined with Enfortumab Vedotin Following Platinum and PD1/L1 Inhibitors for Metastatic Urothelial Carcinoma with FGFR2/3 Genetic Alterations | I | 11/30 | N/A | INTERVENTION |
25 | 10528 | LAO-MA036 | ETCTN | Solid Tumor | Temporarily Closed to Accrual | A Phase 1 Study of the Polymerase Theta Inhibitor Novobiocin in BRCA-Mutant and Other DNA Damage Repair-Deficient Solid Tumors | I | 1/30 | N/A | INTERVENTION |
26 | 10553 | LAO-MD017 | ETCTN | Head and Neck Cancer | Active | A Phase 2 Study of Darolutamide in Combination with Leuprolide Acetate in Hormone-Therapy Naive Recurrent and/or Metastatic Androgen Receptor (AR) Positive Salivary Gland Cancer | II | 4/20 | N/A | INTERVENTION |
27 | 10572 | LAO-CT018 | ETCTN | Solid Tumor | Active | A Phase 1/2 Trial Evaluating the Combination of Temozolomide and the Ataxia Telangiectasia and Rad3-Related Inhibitor M1774 | I/II | 6/42 | 45 | SCREENING, INTERVENTION |
28 | 10355 | LAO-MA036 | ETCTN | Female Reproductive System Cancer;Solid Tumor | Active | A Phase I Study of DS-8201a in Combination with Olaparib in HER2-Expressing Malignancies | I | 27/55 | N/A | INTERVENTION |
29 | 10366 | LAO-MD017 | ETCTN | Gastrointestinal Cancer | Temporarily Closed to Accrual | A Phase 1/2 Study of M3814 (Peposertib) in Combination with Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma | I/II | 19/24 | N/A | INTERVENTION |
30 | 10479 | LAO-CT018 | ETCTN | Endocrine Cancer | Active | A Phase I Dose Escalation-Expansion Trial of Sunitinib Malate Plus Lutetium Lu 177 Dotatate (Lutathera) in Somatostatin Receptor Positive Pancreatic Neuroendocrine Tumors | I | 0/24 | N/A | INTERVENTION |
31 | 10551 | LAO-PA015 | ETCTN | Breast Cancer;Male Reproductive System Cancer;Solid Tumor | Temporarily Closed to Accrual | A Phase I/Ib Study of Anti-CD47 Hu5F9-G4 (Magrolimab) in Combination with Olaparib in Patients with BRCA1/2-Mutant Tumors | I | 0/33 | N/A | INTERVENTION |
32 | 10556 | LAO-NCI | ETCTN | Soft Tissue Cancer/Sarcoma | Temporarily Closed to Accrual | Randomized Phase 2 Study of Cabozantinib, Ipilimumab, and Nivolumab in Patients with Soft Tissue Sarcoma | II | 11/66 | N/A | INTERVENTION |
33 | 10590 | LAO-MD017 | ETCTN | Lymphoma | Active | NORM: Nodular Lymphocyte-Predominant Hodgkin Lymphoma Patients Treated in a Randomized Phase 2 Trial with Either Rituximab or Mosunetuzumab | II | 4/70 | N/A | INTERVENTION |
34 | 10601 | LAO-CA043 | ETCTN | Lymphoma | Active | A Phase 1 Study of Mosunetuzumab with Polatuzumab Vedotin and Lenalidomide (M+Pola+Len) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) | I | 0/30 | N/A | INTERVENTION |
35 | 9846 | LAO-NCI | ETCTN | Hematopoietic Neoplasm (excluding Leukemia, Lymphoma and Myeloma);Solid Tumor | Active | Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI) | Other | N/A | N/A | OTHER |
36 | 10075 | LAO-CA043 | ETCTN | Leukemia | Active | A Phase 1B Study of KRT-232 (AMG-232) in Combination with Decitabine and Venetoclax in Acute Myeloid Leukemia | I | 35/48 | N/A | INTERVENTION |
37 | 10144 | LAO-NCI | ETCTN | Endocrine Cancer;Germ Cell Cancer;Kidney Cancer;Male Reproductive System Cancer;Urothelial/ Bladder Cancer | Active | A Phase II Study of Olaparib (AZD2281) in Patients with Metastatic/Advanced Urothelial Carcinoma and Other Genitourinary Tumors with DNA-Repair Defects | II | 21/60 | 35 | SCREENING, INTERVENTION |
38 | 10204 | LAO-TX035 | ETCTN | Female Reproductive System Cancer;Hematopoietic Neoplasm (excluding Leukemia, Lymphoma and Myeloma);Kidney Cancer;Lung, Mediastinal, and Pleural Cancer;Lymphoma;Skin Cancer;Solid Tumor;Urothelial/ Bladder Cancer | Active | A Phase Ib Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO) | I | 70/312 | N/A | INTERVENTION |
39 | 10285 | LAO-CT018 | ETCTN | Skin Cancer | Active | Phase 1/2 Study of an EZH2 Inhibitor (Tazemetostat) in Combination with Dual BRAF/MEK Inhibition in Patients with BRAF- Mutated Metastatic Melanoma Who Progressed on Prior BRAF/MEK Inhibitor Therapy | I/II | 12/18 | N/A | INTERVENTION |
40 | 10300 | LAO-CT018 | ETCTN | Leukemia | Active | BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1 (BLAST MRD AML-1): A Randomized Phase 2 Study of the Anti-PD-1 Antibody Pembrolizumab in Combination with Conventional Intensive Chemotherapy as Frontline Therapy in Patients with Acute Myeloid Leukemia | II | 43/124 | N/A | INTERVENTION |
41 | 10301 | LAO-CT018 | ETCTN | Male Reproductive System Cancer | Temporarily Closed to Accrual | A Phase I and Randomized Phase II Trial of Radium-223 Dichloride, M3814, & Avelumab in Advanced Metastatic Castrate-Resistant Prostate Cancer (mCRPC) | I/II | 15/24 | N/A | INTERVENTION |
42 | 10302 | LAO-CA043 | ETCTN | Breast Cancer | Active | Phase II Trial of Radium-223 Dichloride in Combination with Paclitaxel in Patients with Bone Metastatic Breast Cancer | II | 67/70 | N/A | INTERVENTION |
43 | 10347 | LAO-CT018 | ETCTN | Lymphoma | Active | A Phase I Study with an Expansion Cohort of Duvelisib and Nivolumab in Mycosis Fungoides (MF) and Sézary Syndrome (SS) | I | 15/33 | N/A | INTERVENTION |
44 | 10371 | LAO-NCI | ETCTN | Breast Cancer;Female Reproductive System Cancer;Gastrointestinal Cancer;Male Reproductive System Cancer;Solid Tumor | Active | A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients with Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response | II | 26/36 | N/A | INTERVENTION |
45 | 10449 | LAO-TX035 | ETCTN | Breast Cancer;Solid Tumor | Active | A Phase 1 Study of ZEN003694 in Combination with Binimetinib in Solid Tumors with RAS Pathway Alterations and Triple Negative Breast Cancer | I | 11/30 | N/A | INTERVENTION |
46 | 10466 | LAO-NCI | ETCTN | Kidney Cancer | Active | A Phase 2 Study of Bevacizumab, Erlotinib and Atezolizumab in Subjects with Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Associated or Sporadic Papillary Renal Cell Cancer | II | 12/42 | 12 | SCREENING, INTERVENTION |
47 | 10486 | LAO-TX035 | ETCTN | Solid Tumor | Active | Phase 2 Trial of the Combination of the BET Inhibitor, ZEN003694 (ZEN-3694), and the PARP Inhibitor Talazoparib, in Patients with Molecularly-Selected Solid Tumors (ComBET) | II | 16/88 | N/A | INTERVENTION |
48 | 10499 | LAO-CT018 | ETCTN | Gastrointestinal Cancer;Lymphoma;Solid Tumor | Active | Phase Ib/II Study of ZEN003694 and Entinostat in Advanced and Refractory Solid Tumors and Lymphomas | I/II | 12/30 | N/A | INTERVENTION |
49 | 10525 | LAO-MA036 | ETCTN | Breast Cancer | Active | A Phase 1b Trial of ZEN003694 (ZEN-3694) with Pembrolizumab and Nab-Paclitaxel in Patients with Metastatic Triple-Negative Breast Cancer | I | 6/57 | N/A | INTERVENTION |
50 | 10605 | LAO-TX035 | ETCTN | Gastrointestinal Cancer | Active | A Phase 1 Study of ZEN003694 (ZEN-3694) in Combination with Cetuximab and Encorafenib in Patients with Refractory BRAF V600E Metastatic Colorectal Cancer | I | 0/30 | N/A | INTERVENTION |